Nurix Therapeutics (NRIX) Total Liabilities (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Total Liabilities data on file, last reported at $132.9 million in Q2 2026.

• On a quarterly basis, Total Liabilities fell 7.67% year-over-year to $132.9 million in Q2 2026; TTM through May 2026 was $132.9 million, a 7.67% decrease from a year earlier, with the FY2025 full-year figure at $149.4 million, up 4.94% from the prior year.
• Total Liabilities for Q2 2026 stood at $132.9 million, down from $155.2 million in the prior quarter.
• Over the last five years, Total Liabilities for NRIX reached as high as $155.2 million in Q1 2026 and fell as low as $74.4 million in Q3 2023.
• Historically, Total Liabilities has averaged $129.7 million across 5 years, with a median of $135.4 million in 2024.
• Across the five-year window, Total Liabilities sank 36.32% in 2023 and jumped 83.85% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $113.1 million in 2022, then jumped by 37.18% to $155.1 million in 2023, then declined by 8.22% to $142.4 million in 2024, then climbed by 4.94% to $149.4 million in 2025, then declined by 11.03% to $132.9 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $132.9 million in Q2 2026, $155.2 million in Q1 2026, and $149.4 million in Q4 2025.